NCT00982254已完成1 期
A Comparison of the Pharmacodynamic and Pharmacokinetic Properties of Oral Insulin vs. s.c. Regular Insulin in Type 2 Diabetic Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Glucose Infusion Rate (GIR)
研究概览
简要总结
This study compared the pharmacokinetic and pharmacodynamic properties of an oral insulin formulation with that of a standard subcutaneous injection of regular human insulin.
详细描述
This study was a single centre, randomized, 3-period crossover study performed in patients with type 2 diabetes. Patients received single doses of an oral insulin formulation and subcutaneous regular human insulin on separate visits.
The primary objective of this study was to compare the pharmacokinetic and pharmacodynamic properties of an oral insulin formulation with that of 15 U subcutaneous injected regular human insulin.
Pharmacokinetic and pharmacodynamic parameters including bioavailability and bioefficacy were measured during 6-hour glucose clamp experiments.
Study duration: 2 months
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 35 Years 至 70 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male subjects between the ages of 35 and 70 years, inclusive, with Type 2 diabetes mellitus as defined by the ADA criteria for more than one year
- •Subjects must have Body Mass Index (BMI) < 36 kg/m²
- •Stable glycemic control (HbA1C <11%)
- •Subjects must be off all oral hypoglycemic agents 24 hours prior to each study dosing day and off any investigational drug for at least 4 weeks
- •Subjects must refrain from strenuous physical activity beginning 72 hours prior to admission and through the duration of the study
- •Subjects must be willing and able to be confined to the Clinical Research Unit as required by the protocol
- •Subjects must be willing and able to provide written informed consent
排除标准
- •History or presence of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, neurological or infectious disorders capable of altering the absorption, metabolism or elimination of drugs, or of constituting a risk factor when taking the study medication
- •Subjects with gastroparesis, orthostatic hypotension and hypoglycemia unawareness (autonomic neuropathy).
- •Subjects with "brittle" diabetes or predisposition to severe hypoglycemia, e.g., 2 or more serious hypoglycemic episodes (requiring another's assistance) within the past year, or any hospitalization or emergency room visit due to poor diabetic control within the past 6 months.
- •Evidence of significant active hematological disease and/or cumulative blood donation of 1 unit (500 mL) or more including blood drawn during clinical trials in the last 3 months
- •Positive hepatitis B (hepatitis B surface antigen) and/or hepatitis C (hepatitis C antibody) serology
- •Positive HIV serology
- •Evidence of significant active neuropsychiatric disease
- •Known allergy to human insulin excipients contained in these products
- •Regular alcohol intake greater than 28 units*/week (male), or 21 units/week (female), or subjects unwilling to stop alcohol for the duration of the study (* 1 unit = 8 g ethanol, ¼ liter of beer or 1 glass wine or 1 measure of spirits)
- •Intake of any drug which in the evaluation of the investigator may interfere with the interpretation of trial results or are known to cause clinically relevant interference with insulin action, glucose utilisation or recovery from hypoglycaemia.
- •Treatment with s.c. insulin injections.
- •Investigators, site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted
- •Have any other condition (including drug abuse, alcohol abuse, or psychiatric disorder) that, in the opinion of the investigator, precludes the patient from following and completing the protocol.
研究组 & 干预措施
Oral Insulin
Experimental
oral insulin capsule formulation
干预措施: Oral insulin (Drug)
Subcutaneous Insulin
Active Comparator
Subcutaneous injection of regular human insulin
干预措施: regular human insulin (Drug)
结局指标
主要结局
Glucose Infusion Rate (GIR)
时间窗: For each treatment continuously from 6 hours before dosing until 6 hours after dosing
次要结局
- Plasma C-Peptide(For each treatment at regular times from 6 hours before dosing until 6 hours after dosing)
- Adverse Events(For each treatment before and after end of clamp)
- Plasma insulin concentration(For each treatment at regular times from 6 hours before dosing until 6 hours after dosing)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70.Type 1 DiabetesNCT00283218University of Aarhus24
已完成
3 期
A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, BIAsp70, BIAsp50 and Fast-acting Human InsulinDiabetes Mellitus, Type 1NCT00888732University of Aarhus24
已完成
1 期
Expanded PK and PD of Insulin Glulisine Versus Insulin Aspart in Healthy VolunteersDiabetesNCT00969592Profil Institut für Stoffwechselforschung GmbH12
已完成
不适用
Pharmacology of Insulin Injected With Jet-InjectionDiabetes Mellitus, Type 1NCT00983775Radboud University Medical Center48
已完成
1 期
A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy PeopleHealthy VolunteersNCT06291285Novo Nordisk A/S44